ResMed Combines Chair, CEO Roles as Mick Farrell Succeeds His Father
ResMed appoints CEO Mick Farrell as chair of the board as the company streamlines its leadership and positions itself for continued growth.
ResMed appoints CEO Mick Farrell as chair of the board as the company streamlines its leadership and positions itself for continued growth.
A $2m funding round will accelerate the company's product development and regulatory and precommercialization efforts as it prepares for a 2024 entry into the North American CPAP market.
OxyGo, makers of portable oxygen concentrators, details its new sleep line.
Trying to decide what to do about narcolepsy treatment during conception, pregnancy, and breastfeeding is a major challenge to people with childbearing potential who are living with narcolepsy.
QUVIVIQ will be the first dual orexin receptor antagonist available in Switzerland for the treatment of chronic insomnia.
The pandemic impacted sleep study wait lists, and this is an opportunity to leverage locally developed technology to help Manitobans.
The COVID-19 pandemic offered researchers a rare opportunity to see the effects of a potentially distressing global event on people with sleep reactivity, that is, those who are vulnerable to stress-related sleep disturbances.
An international group of researchers investigated how shift work affects the risk of COVID-19 and the severity of the infection.
Three dental sleep medicine practitioners share their advice on growing a practice purposefully and impactfully.